US Stock MarketDetailed Quotes
QNRX Quoin Pharmaceuticals
- 0.5471
- -0.0129-2.30%
Close Aug 6 16:00 ET
2.18MMarket Cap-82P/E (TTM)
0.5930High0.5400Low30.85KVolume0.5930Open0.5600Pre Close17.24KTurnover0.78%Turnover RatioLossP/E (Static)3.98MShares6.760052wk High0.24P/B2.17MFloat Cap0.518052wk Low--Dividend TTM3.96MShs Float40500.0000Historical High--Div YieldTTM9.46%Amplitude0.5180Historical Low0.5580Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Quoin Pharmaceuticals Stock Forum
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
Quoin Pharmaceuticals (NASDAQ: QNRX) has announced plans to initiate a clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome (PSS), a rare autosomal disease with no approved treatment. The study will focus on a pediatric patient, with the company actively exploring additional clinical sites in other countries.
QRX003, Quoin's most advanced pipeline product, is alre...
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of 4,062,500 ordinary shares represented by 4,062,500 American Depositary Shares (or pre-funded warrants in lieu thereof), Series D warrants to purchase an aggregate of up to 4,06...
let's hope that's the catalyst needed to get this back over 4
In a significant development that could potentially alter the trajectory of Netherton Syndrome treatment, Quoin Pharmaceuticals (NASDAQ: QNRX) has received clearance from the U.S. Food and Drug Administration (FDA) to include teenage subjects in their ongoing clinical studies. This decision is expected to broaden the ...
No comment yet